Currently, only three predictive biomarkers have been approved by the FDA for ICI therapy in cancers, namely programmed death-ligand 1 (PD-L1), microsatellite instability (MSI) or defective mismatch repair (dMMR), and tumor mutational burden (TMB), while only two predictive biomarkers, namely PD-L1 and MSI/dMMR have been approved by the EMA [57]. The gene discussed is CD274; the disease is cancer.